Why the study?
Does trimetazidine improve left ventricular function and functional status in patients with dilated ischaemic cardiomyopathy?
Population
61 patients with dilated ischaemic cardiomyopathy
Comparison
Trimetazidine 20 mg thrice daily added to… vs Usual drug treatment for 18 months
Design
RCT, randomly assigned
Follow-up
18 months
Authors
Loading...
Supports adjunctive trimetazidine in ischemic cardiomyopathy; extends metabolic modulation evidence in RCT setting.
Does trimetazidine improve left ventricular function and functional status in patients with dilated ischaemic cardiomyopathy?
Trimetazidine added to standard therapy for 18 months improves left ventricular ejection fraction, functional status, and limits the inflammatory response in patients with ischemic dilated cardiomyopathy.
Pericle Di Napoli (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: